Abstract:The host gastrointestinal tract is exposed to countless numbers of foreign antigens and has embedded a unique and complex network of immunological and non-immunological mechanisms, often termed the gastrointestinal 'mucosal barrier', to protect the host from potentially harmful pathogens while at the same time 'tolerating' other resident microbes to allow absorption and utilization of nutrients. Of the many important roles of this barrier, it is the distinct responsibility of the mucosal immune system to sample and discriminate between harmful and beneficial antigens and to prevent entry of food-borne pathogens through the gastrointestinal (GI) tract. This system comprises an immunological network termed the gut-associated lymphoid tissue (GALT) that consists of unique arrangements of B cells, T cells and phagocytes which sample luminal antigens through specialized epithelia termed the follicle associated epithelia (FAE) and orchestrate co-ordinated molecular responses between immune cells and other components of the mucosal barrier. Certain pathogens have developed ways to bypass and/or withstand defence by the mucosal immune system to establish disease in the host. Some 'opportunistic' pathogens (such as Clostridium difficile) take advantage of host or other factors (diet, stress, antibiotic use) which may alter or weaken the response of the immune system. Other pathogens have developed mechanisms for invading gastrointestinal epithelium and evading phagocytosis/destruction by immune system defences. Once cellular invasion occurs, host responses are activated to limit local mucosal damage and repel the foreign influence. Some pathogens (Shigella spp, parasites and viruses) primarily establish localized disease while others (Salmonella, Yersinia, Listeria) use the lymphatic system to enter organs or the bloodstream and cause more systemic illness. In some cases, pathogens (Helicobacter pylori and Salmonella typhi) colonize the GI tract or associated lymphoid structures for extended periods of time and these persistent pathogens may also be potential triggers for other chronic or inflammatory diseases, including inflammatory bowel disease and malignancies. The ability of certain pathogens to avoid or withstand the host's immune assault and/or utilize these host responses to their own advantage (i.e. enhance further colonization) will dictate the pathogen's success in promoting illness and furthering its own survival.

Interactions between gastric and enteric infections: clues to the pathogenesis of inflammatory bowel disease?

An (Anti)-Inflammatory Microbiota: Defining the Role in Inflammatory Bowel Disease?

Microbial-gut interactions in health and disease. Mucosal immune responses

Helicobacter pylori: Does Gastritis Prevent Colitis?

Pathogens in Crohn's Disease: The Role of Adherent Invasive Escherichia coli

Association of Adherent-invasive Escherichia coli with severe Gut Mucosal dysbiosis in Hong Kong Chinese population with Crohn’s disease

Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease?

Relationship between human intestinal dendritic cells, gut microbiota, and disease activity in Crohn's disease

Differential prevalence of pathobionts and host gene polymorphisms in chronic inflammatory intestinal diseases: Crohn's disease and intestinal tuberculosis

P1214 The crosstalk between oral and intestinal microbiota in inflammatory bowel disease patients

Exploring the relationship between Faecalibacterium duncaniae and Escherichia coli in inflammatory bowel disease (IBD): insights and implications

Immune response modulation in inflammatory bowel diseases by Helicobacter pylori infection

Genetic insight into the relationship between inflammatory bowel disease and Clostridioides difficile infection

Gut microbiome and mycobiome in inflammatory bowel disease patients with Clostridioides difficile infection

From gut microflora imbalance to mycobacteria infection: is there a relationship with chronic intestinal inflammatory diseases?

Insight into gut dysbiosis of patients with inflammatory bowel disease and ischemic colitis

Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities

Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care

Intestinal fungi and antifungal secretory immunoglobulin A in Crohn’s disease

The Prevalence of Helicobacter Pylori Infection in Inflammatory Bowel Disease in China: A Case-Control Study

Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection